183 related articles for article (PubMed ID: 22712835)
1. Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.
Khoo TL; Catalano A; Supple S; Chong L; Yeoh SC; Yeung S; Iland H
Leuk Lymphoma; 2013 Jan; 54(1):186-8. PubMed ID: 22712835
[No Abstract] [Full Text] [Related]
2. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia.
Prabhash K; Biswas G; Prasad N; Karant N; Sastry PS; Parikh PM
Indian J Dermatol Venereol Leprol; 2006; 72(1):63-4. PubMed ID: 16481719
[No Abstract] [Full Text] [Related]
3. A patient of chronic myelogenous leukemia developing painful rash on feet.
Kumar P; Das NK; Sil A; Chakrabarti P
J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
[No Abstract] [Full Text] [Related]
4. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M; Sade S; Gilbert M; Klieb HB
Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
[TBL] [Abstract][Full Text] [Related]
5. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
[No Abstract] [Full Text] [Related]
6. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
Ostro D; Lipton J
Leuk Lymphoma; 2007 Jan; 48(1):195-6. PubMed ID: 17325868
[No Abstract] [Full Text] [Related]
7. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
[No Abstract] [Full Text] [Related]
8. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
[No Abstract] [Full Text] [Related]
9. Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.
Mabed M; Elhefni AM; Damnhouri G
Leuk Lymphoma; 2012 Nov; 53(11):2310-1. PubMed ID: 22462614
[No Abstract] [Full Text] [Related]
10. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
Parmar KK; King RS
Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
[No Abstract] [Full Text] [Related]
11. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
Giona F; Mariani S; Gnessi L; Moleti ML; Rea M; De Vellis A; Marzella D; Testi AM; Foà R
Haematologica; 2013 Mar; 98(3):e25-7. PubMed ID: 22983586
[No Abstract] [Full Text] [Related]
12. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
Machaczka M; Gossart M
Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
[No Abstract] [Full Text] [Related]
13. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
[No Abstract] [Full Text] [Related]
14. Imatinib mesylate induced immune thrombocytopenia.
Rajappa S; Varadpande L; Paul TR; Digumarti R
Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
[No Abstract] [Full Text] [Related]
15. Precipitation of porphyria cutanea tarda by imatinib mesylate?
Ho AY; Deacon A; Osborne G; Mufti GJ
Br J Haematol; 2003 Apr; 121(2):375. PubMed ID: 12694262
[No Abstract] [Full Text] [Related]
16. An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
Agarwal A; Eide CA; Harlow A; Corbin AS; Mauro MJ; Druker BJ; Corless CL; Heinrich MC; Deininger MW
Leukemia; 2008 Dec; 22(12):2269-72. PubMed ID: 18509354
[No Abstract] [Full Text] [Related]
17. Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia.
Anzalone CL; Cohen PR; Kurzrock R; Cortes JE
Dermatol Online J; 2014 Jan; 20(1):21242. PubMed ID: 24456946
[TBL] [Abstract][Full Text] [Related]
18. Imatinib for chronic myeloid leukaemia: a NICE mess.
Lim D; Muir J
Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
[No Abstract] [Full Text] [Related]
19. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
Lau YM; Lam YK; Leung KH; Lin SY
Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
[No Abstract] [Full Text] [Related]
20. [Imatinib mesylate-induced acute cytolytic hepatitis].
Rocca P; El Jastimi S; Troncy J; Scoazec JY; Boucher A; Vial T; Trépo C; Zoulim F
Gastroenterol Clin Biol; 2004 Oct; 28(10 Pt 1):918-9. PubMed ID: 15523233
[No Abstract] [Full Text] [Related]
[Next] [New Search]
